Literature DB >> 29125431

The timing of venous thromboembolic events after spine surgery: a single-center experience with 6869 consecutive patients.

Michael B Cloney1, Benjamin Hopkins2, Ekamjeet S Dhillon2, Nader S Dahdaleh1.   

Abstract

OBJECTIVE Venous thromboembolic events (VTEs), including both deep venous thrombosis (DVT) and pulmonary embolism, are a major cause of morbidity and mortality after spine surgery. Prophylactic anticoagulation, or chemoprophylaxis, can prevent VTE. However, the timing of VTEs after spine surgery and the effect of chemoprophylaxis on VTE timing remain underinvestigated. METHODS The records of 6869 consecutive spine surgeries were retrospectively examined. Data on patient demographics, surgical variables, hospital course, and timing of VTEs were collected. Patients who received chemoprophylaxis were compared with those who did not. Appropriate regression models were used to examine selection for chemoprophylaxis and the timing of VTEs. RESULTS Age (OR 1.037, 95% CI 1.023-1.051; p < 0.001), longer surgery (OR 1.003, 95% CI 1.002-1.004; p < 0.001), history of DVT (OR 1.697, 95% CI 1.038-2.776; p = 0.035), and fusion surgery (OR 1.917, 95% CI 1.356-2.709; p < 0.001) predicted selection for chemoprophylaxis. Chemoprophylaxis patients experienced more VTEs (3.62% vs 2.03% of patients, respectively; p < 0.001), and also required longer hospital stays (5.0 days vs 1.0 days; HR 0.5107; p < 0.0001) and had a greater time to the occurrence of VTE (median 6.8 days vs 3.6 days; HR 0.6847; p = 0.0003). The cumulative incidence of VTEs correlated with the postoperative day in both groups (Spearman r = 0.9746, 95% CI 0.9457-0.9883, and p < 0.0001 for the chemoprophylaxis group; Spearman r = 0.9061, 95% CI 0.8065-0.9557, and p < 0.0001 for the nonchemoprophylaxis group), and the cumulative incidence of VTEs was higher in the nonchemoprophylaxis group throughout the 30-day postoperative period. Cumulative VTE incidence and postoperative day were linearly correlated in the first 2 postoperative weeks (R = 0.9396 and p < 0.0001 for the chemoprophylaxis group; R = 0.8190 and p = 0.0003 for the nonchemoprophylaxis group) and the remainder of the 30-day postoperative period (R = 0.9535 and p < 0.0001 for the chemoprophylaxis group; R = 0.6562 and p = 0.0058 for the nonchemoprophylaxis group), but the linear relationships differ between these 2 postoperative periods (p < 0.0001 for both groups). CONCLUSIONS Anticoagulation reduces the cumulative incidence of VTE after spine surgery. The cumulative incidence of VTEs rises linearly in the first 2 postoperative weeks and then plateaus. Surgeons should consider early initiation of chemoprophylaxis for patients undergoing spine surgery.

Entities:  

Keywords:  BMI = body mass index; CPT= Current Procedural Terminology; DVT; DVT = deep venous thrombosis; EBL = estimated blood loss; VTE = venous thromboembolic event; anticoagulation; chemoprophylaxis; deep vein thrombosis; pulmonary embolism; spine surgery; vascular disorders; venous thromboembolism

Mesh:

Substances:

Year:  2017        PMID: 29125431     DOI: 10.3171/2017.5.SPINE161399

Source DB:  PubMed          Journal:  J Neurosurg Spine        ISSN: 1547-5646


  3 in total

1.  Venous Thromboembolism After Degenerative Spine Surgery: A Nationwide Readmissions Database Analysis.

Authors:  Ian A Buchanan; Michelle Lin; Daniel A Donoho; Li Ding; Steven L Giannotta; Frank Attenello; William J Mack; John C Liu
Journal:  World Neurosurg       Date:  2019-01-23       Impact factor: 2.104

2.  Time-to-event analyses of lower-limb venous thromboembolism in aged patients undergoing lumbar spine surgery: a retrospective study of 1620 patients.

Authors:  Liang Li; Zhaohui Li; Yachong Huo; Dalong Yang; Wenyuan Ding; Sidong Yang
Journal:  Aging (Albany NY)       Date:  2019-10-15       Impact factor: 5.682

3.  Risk Factors for Venous Thrombosis after Spinal Surgery: A Systematic Review and Meta-analysis.

Authors:  Sheng Wang; Leilei Wu
Journal:  Comput Math Methods Med       Date:  2022-03-27       Impact factor: 2.238

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.